达格列净对老年2型糖尿病合并心力衰竭患者代谢水平的影响  

Effects of Daggligin on Metabolism in Elderly Patients with Type 2 Diabetes and Heart Failure

作　　者：孔越 曹彩霞[1] 孙茜[1] 代黎明 徐音飞 潘晓彤 

机构地区：[1]青岛大学附属医院老年医学科,山东 青岛

出　　处：《临床医学进展》2023年第4期5520-5526,共7页Advances in Clinical Medicine

摘　　要：目的:探索达格列净(Dapagliflozin)对老年2型糖尿病合并心力衰竭患者血脂及尿酸代谢水平的影响。方法:选取2021年1月~2022年1月我院收治的105例老年2型糖尿病合并心力衰竭患者为研究对象,其中应用达格列净的患者55例,2型糖尿病合并心力衰竭未应用达格列净的患者50例,并且随访观察6个月。比较治疗前和治疗后3个月及6个月治疗组与安慰剂组的变化。结果:达格列净治疗组治疗后患者血脂及尿酸代谢水平均较前好转,且6个月较3个月效果更佳,与安慰剂组相比P < 0.05,有统计学意义。结论:达格列净治疗组治疗后患者血脂及尿酸水平均较前好转,且随时间延长,效果更佳。Objective: To explore the effect of dapagliflozin on blood lipid and uric acid metabolism in the aged patients with type 2 diabetes mellitus and heart failure. Methods: Select 105 aged patients with type 2 diabetes mellitus and heart failure admitted to our hospital from January 2021 to January 2022 as the subjects of study, including 55 patients who were treated with dapagliflozin and 50 pa-tients with type 2 diabetes mellitus and heart failure who were not treated with dapagliflozin, and were followed up for 6 months. Compare the changes between the treatment group and the placebo group before treatment and 3 and 6 months after treatment. Results: After treatment, the blood li-pid and uric acid metabolism levels of patients in the dapagliflozin treatment group were improved, and the effect of 6 months was better than that of 3 months, P < 0.05 compared with the placebo group, with statistical significance. Conclusion: The blood lipid and uric acid levels of patients in the dapagliflozin treatment group were improved after treatment, and the effect was better with time.

关 键 词：SGLT2抑制剂 达格列净 老年人 2型糖尿病 心力衰竭 代谢水平 

分 类 号：R54[医药卫生—心血管疾病]